Emerging studies suggest this peptide, a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could offer a promising advancement for weight loss . Preliminary patient trials have shown substantial losses in visceral fat , possibly surpassing existing weight-loss m